Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+4.17%
$40.30
100% positive prob.
5-Day Prediction
+7.66%
$41.65
100% positive prob.
20-Day Prediction
+9.02%
$42.18
95% positive prob.
SEC 8-K filings with transcript text
Jan 28, 2026 · 100% conf.
1D
+4.17%
$40.30
5D
+7.66%
$41.65
20D
+9.02%
$42.18
cnmd-20260128FALSE000081695600008169562026-01-282026-01-28
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15 (d) OF THE
Date of Report (Date of earliest event reported): January 28, 2026
(Exact name of registrant as specified in its charter)
Delaware001-3921816-0977505 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
11311 Concept Blvd Largo, FL 33773 (Address of principal executive offices)(Zip code)
(727) 392-6464 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of the Act
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par valueCNMDNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition
On January 28, 2026, CONMED Corporation issued a press release announcing financial results for the fourth quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are included herewith:
Exhibit No.Description of Exhibit 99.1Press release dated January 28, 2026, issued by CONMED Corporation.
104Cover Page Interactive Data File (embedded within the Inline XBRL Document).
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 28, 2026
(Registrant)
By: /s/ Todd W. Garner Name:Todd W. Garner Title:Executive Vice President, Finance & Chief Financial Officer
Nov 5, 2025
cnmd-20251105FALSE000081695600008169562025-11-052025-11-05
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15 (d) OF THE
Date of Report (Date of earliest event reported): November 5, 2025
(Exact name of registrant as specified in its charter)
Delaware001-3921816-0977505 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
11311 Concept Blvd Largo, FL 33773 (Address of principal executive offices)(Zip code)
(727) 392-6464 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of the Act
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par valueCNMDNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition
On November 5, 2025, CONMED Corporation issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are included herewith:
Exhibit No.Description of Exhibit 99.1Press release dated November 5, 2025, issued by CONMED Corporation.
104Cover Page Interactive Data File (embedded within the Inline XBRL Document).
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2025
(Registrant)
By: /s/ Todd W. Garner Name:Todd W. Garner Title:Executive Vice President, Finance & Chief Financial Officer
Jul 30, 2025
cnmd-20250730FALSE000081695600008169562025-07-302025-07-30
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15 (d) OF THE
Date of Report (Date of earliest event reported): July 30, 2025
(Exact name of registrant as specified in its charter)
Delaware001-3921816-0977505 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
11311 Concept Blvd Largo, FL 33773 (Address of principal executive offices)(Zip code)
(727) 392-6464 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of the Act
Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par valueCNMDNYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition
On July 30, 2025, CONMED Corporation issued a press release announcing financial results for the second quarter ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are included herewith:
Exhibit No.Description of Exhibit 99.1Press release dated July 30, 2025, issued by CONMED Corporation.
104Cover Page Interactive Data File (embedded within the Inline XBRL Document).
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 30, 2025
(Registrant)
By: /s/ Todd W. Garner Name:Todd W. Garner Title:Executive Vice President, Finance & Chief Financial Officer
This page provides CONMED Corporation (CNMD) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CNMD's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.